• 1
    Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996; 14: 639643.
  • 2
    Ray-Coquard I, Ghesquière H, Bachelot T, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumors and lymphomas. Br J Cancer. 2001; 85: 816822.
  • 3
    Sculier JP, Weerts D, Klastersky J, et al. Causes of deaths in febrile granulocytopenic cancer patients receiving empiric antibody therapy. Eur J Cancer Clin Oncol. 1984; 20: 5560.
  • 4
    Hussain M, Kish JA, Crane L, et al. The role of infection in the morbidity and mortality of patients with head and neck cancer undergoing multimodality therapy. Cancer. 1991; 67: 716721.
  • 5
    Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11: 12761285.
  • 6
    Fisher IR, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 7
    Radford JA, Ryder WDJ, Dodwell D, et al. Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer. 1993; 29: 8186.
  • 8
    Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced non small cell lung cancer. Cancer. 1998; 82: 116126.
  • 9
    Blay JY, Lecesne A, Mermet C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood. 1998; 92: 405410.
  • 10
    Ray-Coquard I, LeCesne A, Rubio M, et al. A risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol. 1999; 17: 28402846.
  • 11
    Blay JY, Ray-Coquard I, van Glabbeke M, et al. Lymphopenia as an independent prognostic factor for survival in advanced carcinomas, soft tissue sarcomas and lymphomas [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 2591.
  • 12
    Riesco A. Five year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970; 25: 135140.
  • 13
    Kotsakis A, Sarra E, Peraki M, et al. Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis. Cancer. 2000; 89: 13801386.
  • 14
    Reckzeh B, Merte H, Pfluger KH, et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol. 1997; 15: 24762481.
  • 15
    Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis. 1997; 25: 219220.
  • 16
    Porter DR, Marshall DA, Madhok R, et al. Pneumocystis carinii infection complicating cytotoxic therapy in two patients with lymphopenia, but a normal total white cell count. Br J Rheumatol. 1992; 31: 643644.
  • 17
    Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003; 88: 181186.
  • 18
    Little RF, Gutierrez M, Jaffe ES, Pau A, Horne M, Wilson W. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA. 2001; 11: 18801885.
  • 19
    Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for clinical use of hematopoietic colony stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol. 2000; 18: 35583585.
  • 20
    J-Y Blay S, Negrier V, Combaret S, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 33173322.